logo-loader
Arecor

Arecor doses first patient in Phase I trial for ultra-rapid acting insulin product

Dr Sarah Howell, chief executive of Arecor, speaks to Proactive London after announcing the dosing of the first patient in a Phase I clinical trial for its ultra-rapid acting insulin product candidate AT247.

AT247 is an ultra-rapid acting product candidate targeting improved treatment for people living with Type I diabetes.

The trial is being carried out in Austria with preliminary results expected towards the end of the year.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arecor strengthens team with appointment of experienced chief financial officer

Sarah Howell, chief executive of Arecor, spoke to Proactive London's Andrew Scott following the appointment of Susan Lowther as the company's new CFO. Howell says Susan brings a depth of financial and business expertise that'll help them deliver on their ambitious growth plans.

on 11/3/19

2 min read